REAL WORLD EVIDENCE ON THE EFFECTIVENESS OF RIBOCICLIB PLUS AROMATASE INHIBITORS AS FIRST-LINE TREATMENT OF BRAZILIAN PATIENTS WITH HORMONE RECEPTOR-POSITIVE/ HER2-NEGATIVE ADVANCED BREAST CANCER (HR+/HER2–ABC): THE BRASILEEIRA STUDY